
Accordingly, there is an ongoing medical need to develop new drugs to treat these indications.

SUMMARY

In one aspect the present disclosure provides for compounds of formula (I) or pharmaceutically acceptable salt thereof,



(I)

wherein

R^x is hydrogen;

R^y is C_1-C_3 alkyl;

A^1 is CR^1, A^2 is CR^2, A^3 is CR^3; and A^4 is CR^4;

R^1 is hydrogen

R^2 is hydrogen, $-S(O)_2R^{2a}$, or $-N(R^{2b})S(O)_2R^{2a}$;

wherein R^{2a} is C_1-C_6 alkyl or C_1-C_6 haloalkyl; and R^{2b} and R^{2c} are each independently hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

L^1 is O, N(H), or OCH_2 wherein the CH_2 moiety of OCH_2 is attached to G^1;

R^{x1}, G^1, R^3, and R^4, are selected from (i), (ii), (iii), or (iv);

(i) R^{x1} is, $-G^{x1}$-G^{x2}, -(C_1-C_6 alkylenyl)-G^{x1}-G^{x2}, $-C(O)N(R^{xa})(R^{xb})$, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_2-C_6 alkenyl and C_2-C_6 alkynyl are each independently substituted with one substituent selected from the group consisting of -CN, $-OR^{xc}$, $-SR^{xc}$, $-S(O)R^{xc}$, $-S(O)_2R^{xc}$, $-NR^{xa}R^{xc}$, $-C(O)R^{xc}$, $-C(O)OR^{xc}$, $-C(O)NR^{xa}R^{xc}$, $-S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of R^u and R^v groups;

R^3 is R^{1a}, -C(O)OH, -C(O)$NR^{3a}R^{3b}$, -$NR^{3a}R^{3b}$, G^{3a}, -G^{3a}-G^{3b}, -(C_1-C_6 alkylenyl)-OR^{3a}, -(C_1-C_6 alkylenyl)-$NR^{3a}R^{3b}$, -(C_1-C_6 alkylenyl)-G^{3a}, or -(C_1-C_6 alkylenyl)-G^{3a}-G^{3b}; and

R^4 is R^{1a} or G^4;

(ii) R^{x1} is –CN, -G^{x1}-G^{x2}, -(C_1-C_6 alkylenyl)-G^{x1}-G^{x2}, -C(O)N(R^{xa})(R^{xb}), hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -C(O)OR^{ax1}, -C(O)$NR^{bx1}R^{cx1}$, -C(O)R^{dx1}, -$S(O)_2R^{dx1}$, -$S(O)_2NR^{bx1}R^{cx1}$, G^{x1}, C_1-C_6 haloalkyl, or C_1-C_6 alkyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl are each optionally substituted with one substituent selected from the group consisting of -CN, -OR^{xc}, -SR^{xc}, -S(O)R^{xc}, -$S(O)_2R^{xc}$, -$NR^{xa}R^{xc}$, -C(O)R^{xc}, -C(O)OR^{xc}, -C(O)$NR^{xa}R^{xc}$, -$S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is substituted with one R^u group and is optionally further substituted with 1, 2, 3, 4, or 5 R^v groups;

R^3 is R^{1a}, -C(O)OH, -C(O)$NR^{3a}R^{3b}$, -$NR^{3a}R^{3b}$, G^{3a}, -G^{3a}-G^{3b}, -(C_1-C_6 alkylenyl)-OR^{3a}, -(C_1-C_6 alkylenyl)-$NR^{3a}R^{3b}$, -(C_1-C_6 alkylenyl)-G^{3a}, or -(C_1-C_6 alkylenyl)-G^{3a}-G^{3b}; and

R^4 is R^{1a} or G^4;

(iii) R^{x1} is –CN, -G^{x1}-G^{x2}, -(C_1-C_6 alkylenyl)-G^{x1}-G^{x2}, -C(O)N(R^{xa})(R^{xb}), hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -C(O)OR^{ax1}, -C(O)$NR^{bx1}R^{cx1}$, -C(O)R^{dx1}, -$S(O)_2R^{dx1}$, -$S(O)_2NR^{bx1}R^{cx1}$, G^{x1}, C_1-C_6 haloalkyl, or C_1-C_6 alkyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl are each optionally substituted with one substituent selected from the group consisting of -CN, -OR^{xc}, -SR^{xc}, -S(O)R^{xc}, -$S(O)_2R^{xc}$, -$NR^{xa}R^{xc}$, -C(O)R^{xc}, -C(O)OR^{xc}, -C(O)$NR^{xa}R^{xc}$, -$S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of R^u and R^v groups;

R^3 is -C(O)OH, -C(O)$NR^{3a}R^{3b}$, -$NR^{3a}R^{3b}$, G^{3a}, -G^{3a}-G^{3b}, -(C_1-C_6 alkylenyl)-OR^{3a}, -(C_1-C_6 alkylenyl)-$NR^{3a}R^{3b}$, -(C_1-C_6 alkylenyl)-G^{3a}, or -(C_1-C_6 alkylenyl)-G^{3a}-G^{3b}; and

R^4 is R^{1a} or G^4;

(iv) R^{x1} is –CN, $-G^{x1}-G^{x2}$, $-(C_1-C_6$ alkylenyl$)-G^{x1}-G^{x2}$, $-C(O)N(R^{xa})(R^{xb})$, hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)OR^{ax1}$, $-C(O)NR^{bx1}R^{cx1}$, $-C(O)R^{dx1}$, $-S(O)_2R^{dx1}$, $-S(O)_2NR^{bx1}R^{cx1}$, G^{x1}, C_1-C_6 haloalkyl, or C_1-C_6 alkyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl are each optionally substituted with one substituent selected from the group consisting of -CN, $-OR^{xc}$, $-SR^{xc}$, $-S(O)R^{xc}$, $-S(O)_2R^{xc}$, $-NR^{xa}R^{xc}$, $-C(O)R^{xc}$, $-C(O)OR^{xc}$, $-C(O)NR^{xa}R^{xc}$, $-S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of R^u and R^v groups;

R^3 is R^{1a}, -C(O)OH, $-C(O)NR^{3a}R^{3b}$, $-NR^{3a}R^{3b}$, G^{3a}, $-G^{3a}-G^{3b}$, $-(C_1-C_6$ alkylenyl$)-OR^{3a}$, $-(C_1-C_6$ alkylenyl$)-NR^{3a}R^{3b}$, $-(C_1-C_6$ alkylenyl$)-G^{3a}$, or $-(C_1-C_6$ alkylenyl$)-G^{3a}-G^{3b}$; and

R^4 is G^4;

R^{xa}, at each occurrence, is independently hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

R^{xb}, at each occurrence, is independently C_1-C_6 alkyl substituted with one substituent selected from the group consisting of –CN, $-OR^{ax1}$, $-SR^{ax1}$, $-S(O)R^{dx1}$, $-S(O)_2R^{dx1}$, $-NR^{bx1}R^{cx1}$, $-C(O)R^{ax1}$, $-C(O)OR^{ax1}$, $-C(O)NR^{bx1}R^{cx1}$, and $-S(O)_2NR^{bx1}R^{cx1}$;

R^{xc}, at each occurrence, is independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^a, $-(C_1-C_6$ alkylenyl$)-G^a$, or R^{xb};

R^{ax1}, R^{bx1}, and R^{cx1}, at each occurrence, are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^a, or $-(C_1-C_6$ alkylenyl$)-G^a$;

R^{dx1}, at each occurrence, is independently C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^a, or $-(C_1-C_6$ alkylenyl$)-G^a$;

R^{1a}, at each occurrence, is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, CN, or NO_2;

R^{3a} and R^{3b}, at each occurrence, are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^{3a}, $-G^{3a}-G^{3b}$, $-(C_1-C_6$ alkylenyl$)-G^{3a}$, $-(C_1-C_6$ alkylenyl$)-G^{3a}-G^{3b}$, or $C_{2\text{-}4}-C_6$ alkyl substituted with one substituents selected from the group consisting of –CN, $-OR^h$, $-SR^h$, $-S(O)R^i$, $-S(O)_2R^h$, $-NR^jR^k$, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NR^jR^k$, and $-S(O)_2NR^jR^k$;

G^4, at each occurrence, is independently phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C_1-C_6 alkyl, NO_2, halogen, C_1-C_6 haloalkyl, -CN, oxo, $-OR^h$, $-SR^h$, $-S(O)_2R^h$, and $-NR^jR^k$;

R^u, at each occurrence, is independently –(C_1-C_6 alkylenyl)-G^u, –(C_2-C_6 alkynylene)-G^u, –(C_1-C_6 alkylenyl)-SR^h, -C(O)-Z^1, -C(O)-NZ^1Z^2, $-S(O)_2$-Z^1, $-N(Z^2)Z^1$, or $-N(Z^2)S(O)_2$-Z^1; wherein Z^1 is G^u, -(C_1-C_6 alkylenyl)-G^u, -(C_2-C_6 alkenylene)-G^u, -(C_1-C_6 alkylenyl)-CN, -(C_1-C_6 alkylenyl)-SR^h, -(C_1-C_6 alkylenyl)-OR^h, -(C_1-C_6 alkylenyl)-NR^jR^k, or -(C_1-C_6 alkylenyl)-C_1-C_4 alkoxy-C_1-C_4 alkoxy, and Z^2 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

G^u, at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl, wherein each G^u is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, -CN, oxo, NO_2, $-OR^h$, -O-(C_2-C_6 alkylenyl)-NR^jR^k, $-OC(O)R^i$, $-OC(O)NR^jR^k$, $-SR^h$, $-S(O)_2R^h$, $-S(O)_2NR^jR^k$, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NR^jR^k$, $-NR^jR^k$, $-N(R^h)C(O)R^i$, $-N(R^h)S(O)_2R^i$, $-N(R^h)C(O)O(R^i)$, $-N(R^h)C(O)NR^jR^k$, G^{ua}, -(C_1-C_6 alkylenyl)-OR^h, –(C_1-C_6 alkylenyl)-$OC(O)R^i$, -(C_1-C_6 alkylenyl)-$OC(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-SR^h, –(C_1-C_6 alkylenyl)-$S(O)_2R^h$, –(C_1-C_6 alkylenyl)-$S(O)_2NR^jR^k$, -(C_1-C_6 alkylenyl)-$C(O)R^h$, –(C_1-C_6 alkylenyl)-$C(O)OR^h$, -(C_1-C_6 alkylenyl)-$C(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-NR^jR^k, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)R^i$, -(C_1-C_6 alkylenyl)-$N(R^h)S(O)_2R^i$, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)O(R^i)$, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)NR^jR^k$, -(C_1-C_6 alkylenyl)-CN, and -(C_1-C_6 alkylenyl)-G^{ua};

G^a, G^{x1}, G^{x2}, G^{3a}, G^{3b}, and G^{ua}, at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^z groups;


R^z and R^v, at each occurrence, are each independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, -CN, oxo, NO_2, $-OR^h$, $-OC(O)R^i$, $-OC(O)NR^jR^k$, $-SR^h$, $-S(O)_2R^h$, $-S(O)_2NR^jR^k$, $-C(O)R^h$, $-C(O)OR^h$, $-C(O)NR^jR^k$, $-NR^jR^k$, $-N(R^h)C(O)R^i$, $-N(R^h)S(O)_2R^i$, $-N(R^h)C(O)O(R^i)$, $-N(R^h)C(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-OR^h, –(C_1-C_6 alkylenyl)-$OC(O)R^i$, -(C_1-C_6 alkylenyl)-$OC(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-SR^h, –(C_1-C_6

alkylenyl)-$S(O)_2R^h$, –(C_1-C_6 alkylenyl)-$S(O)_2NR^jR^k$, -(C_1-C_6 alkylenyl)-$C(O)R^h$, –(C_1-C_6 alkylenyl)-$C(O)OR^h$, -(C_1-C_6 alkylenyl)-$C(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-NR^jR^k, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)R^i$, -(C_1-C_6 alkylenyl)-$N(R^h)S(O)_2R^i$, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)O(R^i)$, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)NR^jR^k$, or -(C_1-C_6 alkylenyl)-CN;

R^h, R^j, R^k, at each occurrence, are each independently hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl; and

R^i, at each occurrence, is independently C_1-C_6 alkyl or C_1-C_6 haloalkyl.

In another aspect, the present disclosure provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^x is hydrogen;

R^y is C_1-C_3 alkyl;

A^1 is N or CR^1, A^2 is N or CR^2, A^3 is N or CR^3; and A^4 is N or CR^4; wherein zero, one, two, or three of A^1, A^2, A^3, and A^4 are N;

R^1 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, CN, or NO_2;


R^2 is hydrogen, -$S(O)_2R^{2a}$, -$S(O)_2NR^{2b}R^{2c}$, -$N(R^{2b})S(O)_2R^{2a}$, or -(C_1-C_6 alkylenyl)-$S(O)_2R^{2a}$; wherein R^{2a} is C_1-C_6 alkyl or C_1-C_6 haloalkyl; and R^{2b} and R^{2c} are each independently hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

L^1 is O, N(H), or OCH_2 wherein the CH_2 moiety of OCH_2 is attached to G^1;

R^{x1}, G^1, R^3, and R^4, are selected from (i), (ii), (iii), or (iv);

CLAIMS:

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:



(I)

wherein

R^x is hydrogen;

R^y is C_1-C_3 alkyl;

A^1 is CR^1, A^2 is CR^2, A^3 is CR^3; and A^4 is CR^4;

R^1 is hydrogen

R^2 is hydrogen, $-S(O)_2R^{2a}$, or $-N(R^{2b})S(O)_2R^{2a}$;

wherein R^{2a} is C_1-C_6 alkyl or C_1-C_6 haloalkyl; and R^{2b} and R^{2c} are each independently hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

L^1 is O, N(H), or OCH_2 wherein the CH_2 moiety of OCH_2 is attached to G^1;

R^{x1}, G^1, R^3, and R^4, are selected from (i), (ii), (iii), or (iv);

(i) R^{x1} is, $-G^{x1}$-G^{x2}, -(C_1-C_6 alkylenyl)-G^{x1}-G^{x2}, $-C(O)N(R^{xa})(R^{xb})$, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_2-C_6 alkenyl and C_2-C_6 alkynyl are each independently substituted with one substituent selected from the group consisting of -CN, $-OR^{xc}$, $-SR^{xc}$, $-S(O)R^{xc}$, $-S(O)_2R^{xc}$, $-NR^{xa}R^{xc}$, $-C(O)R^{xc}$, $-C(O)OR^{xc}$, $-C(O)NR^{xa}R^{xc}$, $-S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of R^u and R^v groups;

R^3 is R^{1a}, -C(O)OH, $-C(O)NR^{3a}R^{3b}$, $-NR^{3a}R^{3b}$, G^{3a}, $-G^{3a}$-G^{3b}, -(C_1-C_6 alkylenyl)-OR^{3a}, -(C_1-C_6 alkylenyl)-$NR^{3a}R^{3b}$, -(C_1-C_6 alkylenyl)-G^{3a}, or -(C_1-C_6 alkylenyl)-G^{3a}-G^{3b}; and

R^4 is R^{1a} or G^4;

(ii) R^{x1} is –CN, $-G^{x1}-G^{x2}$, $-(C_1-C_6$ alkylenyl$)-G^{x1}-G^{x2}$, $-C(O)N(R^{xa})(R^{xb})$, hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)OR^{ax1}$, $-C(O)NR^{bx1}R^{cx1}$, $-C(O)R^{dx1}$, $-S(O)_2R^{dx1}$, $-S(O)_2NR^{bx1}R^{cx1}$, G^{x1}, C_1-C_6 haloalkyl, or C_1-C_6 alkyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl are each optionally substituted with one substituent selected from the group consisting of -CN, $-OR^{xc}$, $-SR^{xc}$, $-S(O)R^{xc}$, $-S(O)_2R^{xc}$, $-NR^{xa}R^{xc}$, $-C(O)R^{xc}$, $-C(O)OR^{xc}$, $-C(O)NR^{xa}R^{xc}$, $-S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is substituted with one R^u group and is optionally further substituted with 1, 2, 3, 4, or 5 R^v groups;

R^3 is R^{1a}, -C(O)OH, $-C(O)NR^{3a}R^{3b}$, $-NR^{3a}R^{3b}$, G^{3a}, $-G^{3a}-G^{3b}$, $-(C_1-C_6$ alkylenyl$)-OR^{3a}$, $-(C_1-C_6$ alkylenyl$)-NR^{3a}R^{3b}$, $-(C_1-C_6$ alkylenyl$)-G^{3a}$, or $-(C_1-C_6$ alkylenyl$)-G^{3a}-G^{3b}$; and

R^4 is R^{1a} or G^4;

(iii) R^{x1} is –CN, $-G^{x1}-G^{x2}$, $-(C_1-C_6$ alkylenyl$)-G^{x1}-G^{x2}$, $-C(O)N(R^{xa})(R^{xb})$, hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)OR^{ax1}$, $-C(O)NR^{bx1}R^{cx1}$, $-C(O)R^{dx1}$, $-S(O)_2R^{dx1}$, $-S(O)_2NR^{bx1}R^{cx1}$, G^{x1}, C_1-C_6 haloalkyl, or C_1-C_6 alkyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl are each optionally substituted with one substituent selected from the group consisting of -CN, $-OR^{xc}$, $-SR^{xc}$, $-S(O)R^{xc}$, $-S(O)_2R^{xc}$, $-NR^{xa}R^{xc}$, $-C(O)R^{xc}$, $-C(O)OR^{xc}$, $-C(O)NR^{xa}R^{xc}$, $-S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of R^u and R^v groups;

R^3 is -C(O)OH, $-C(O)NR^{3a}R^{3b}$, $-NR^{3a}R^{3b}$, G^{3a}, $-G^{3a}-G^{3b}$, $-(C_1-C_6$ alkylenyl$)-OR^{3a}$, $-(C_1-C_6$ alkylenyl$)-NR^{3a}R^{3b}$, $-(C_1-C_6$ alkylenyl$)-G^{3a}$, or $-(C_1-C_6$ alkylenyl$)-G^{3a}-G^{3b}$; and

R^4 is R^{1a} or G^4;

(iv) R^{x1} is –CN, $-G^{x1}-G^{x2}$, $-(C_1-C_6$ alkylenyl$)-G^{x1}-G^{x2}$, $-C(O)N(R^{xa})(R^{xb})$, hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)OR^{ax1}$, $-C(O)NR^{bx1}R^{cx1}$, $-C(O)R^{dx1}$, $-S(O)_2R^{dx1}$, $-S(O)_2NR^{bx1}R^{cx1}$, G^{x1}, C_1-C_6 haloalkyl, or C_1-C_6 alkyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl,

and C_2-C_6 alkynyl are each optionally substituted with one substituent selected from the group consisting of -CN, -OR^{xc}, -SR^{xc}, -$S(O)R^{xc}$, -$S(O)_2R^{xc}$, -$NR^{xa}R^{xc}$, -$C(O)R^{xc}$, -$C(O)OR^{xc}$, -$C(O)NR^{xa}R^{xc}$, -$S(O)_2NR^{xa}R^{xc}$, and G^{x1};

G^1 is phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; wherein each G^1 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of R^u and R^v groups;

R^3 is R^{1a}, -C(O)OH, -$C(O)NR^{3a}R^{3b}$, -$NR^{3a}R^{3b}$, G^{3a}, -G^{3a}-G^{3b}, -(C_1-C_6 alkylenyl)-OR^{3a}, -(C_1-C_6 alkylenyl)-$NR^{3a}R^{3b}$, -(C_1-C_6 alkylenyl)-G^{3a}, or -(C_1-C_6 alkylenyl)-G^{3a}-G^{3b}; and

R^4 is G^4;

R^{xa}, at each occurrence, is independently hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

R^{xb}, at each occurrence, is independently C_1-C_6 alkyl substituted with one substituent selected from the group consisting of –CN, -OR^{ax1}, -SR^{ax1}, -$S(O)R^{dx1}$, -$S(O)_2R^{dx1}$, -$NR^{bx1}R^{cx1}$, -$C(O)R^{ax1}$, -$C(O)OR^{ax1}$, -$C(O)NR^{bx1}R^{cx1}$, and -$S(O)_2NR^{bx1}R^{cx1}$;

R^{xc}, at each occurrence, is independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^a, -(C_1-C_6 alkylenyl)-G^a, or R^{xb};

R^{ax1}, R^{bx1}, and R^{cx1}, at each occurrence, are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^a, or -(C_1-C_6 alkylenyl)-G^a;

R^{dx1}, at each occurrence, is independently C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^a, or -(C_1-C_6 alkylenyl)-G^a;

R^{1a}, at each occurrence, is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, CN, or NO_2;

R^{3a} and R^{3b}, at each occurrence, are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, G^{3a}, -G^{3a}-G^{3b}, -(C_1-C_6 alkylenyl)-G^{3a}, -(C_1-C_6 alkylenyl)-G^{3a}-G^{3b}, or $C_{2\ 4}$-C_6 alkyl substituted with one substituents selected from the group consisting of –CN, -OR^h, -SR^h, -$S(O)R^i$, -$S(O)_2R^h$, -NR^jR^k, -$C(O)R^h$, -$C(O)OR^h$, -$C(O)NR^jR^k$, and -$S(O)_2NR^jR^k$;

G^4, at each occurrence, is independently phenyl, C_3-C_6 cycloalkyl, C_5-C_6 heteroaryl, or C_4-C_6 heterocycle; each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C_1-C_6 alkyl, NO_2, halogen, C_1-C_6 haloalkyl, -CN, oxo, -OR^h, -SR^h, -$S(O)_2R^h$, and -NR^jR^k;

R^u, at each occurrence, is independently –(C_1-C_6 alkylenyl)-G^u, –(C_2-C_6 alkynylene)-G^u, –(C_1-C_6 alkylenyl)-SR^h, -C(O)-Z^1, -C(O)-NZ^1Z^2, -$S(O)_2$-Z^1, -$N(Z^2)Z^1$, or -$N(Z^2)S(O)_2$-Z^1; wherein Z^1 is G^u, -(C_1-C_6 alkylenyl)-G^u, -(C_2-C_6 alkenylene)-G^u, -(C_1-C_6 alkylenyl)-CN, -(C_1-C_6 alkylenyl)-SR^h, -(C_1-C_6 alkylenyl)-OR^h, -(C_1-C_6 alkylenyl)-NR^jR^k, or -(C_1-C_6 alkylenyl)-C_1-C_4 alkoxy-C_1-C_4 alkoxy, and Z^2 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

G^u, at each occurrence, is independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl, wherein each G^u is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, -CN, oxo, NO_2, -OR^h, -O-(C_2-C_6 alkylenyl)-NR^jR^k, -$OC(O)R^i$, -$OC(O)NR^jR^k$, -SR^h, -$S(O)_2R^h$, -$S(O)_2NR^jR^k$, -$C(O)R^h$, -$C(O)OR^h$, -$C(O)NR^jR^k$, -NR^jR^k, -$N(R^h)C(O)R^i$, -$N(R^h)S(O)_2R^i$, -$N(R^h)C(O)O(R^i)$, -$N(R^h)C(O)NR^jR^k$, G^{ua}, -(C_1-C_6 alkylenyl)-OR^h, –(C_1-C_6 alkylenyl)-$OC(O)R^i$, -(C_1-C_6 alkylenyl)-$OC(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-SR^h, –(C_1-C_6 alkylenyl)-$S(O)_2R^h$, –(C_1-C_6 alkylenyl)-$S(O)_2NR^jR^k$, -(C_1-C_6 alkylenyl)-$C(O)R^h$, –(C_1-C_6 alkylenyl)-$C(O)OR^h$, -(C_1-C_6 alkylenyl)-$C(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-NR^jR^k, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)R^i$, -(C_1-C_6 alkylenyl)-$N(R^h)S(O)_2R^i$, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)O(R^i)$, –(C_1-C_6 alkylenyl)-$N(R^h)C(O)NR^jR^k$, -(C_1-C_6 alkylenyl)-CN, and -(C_1-C_6 alkylenyl)-G^{ua};

G^a, G^{x1}, G^{x2}, G^{3a}, G^{3b}, and G^{ua}, at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^z groups;

R^z and R^v, at each occurrence, are each independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, -CN, oxo, NO_2, -OR^h, -$OC(O)R^i$, -$OC(O)NR^jR^k$, -SR^h, -$S(O)_2R^h$, -$S(O)_2NR^jR^k$, -$C(O)R^h$, -$C(O)OR^h$, -$C(O)NR^jR^k$, -NR^jR^k, -$N(R^h)C(O)R^i$, -$N(R^h)S(O)_2R^i$, -$N(R^h)C(O)O(R^i)$, -$N(R^h)C(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-OR^h, –(C_1-C_6 alkylenyl)-$OC(O)R^i$, -(C_1-C_6 alkylenyl)-$OC(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-SR^h, –(C_1-C_6 alkylenyl)-$S(O)_2R^h$, –(C_1-C_6 alkylenyl)-$S(O)_2NR^jR^k$, -(C_1-C_6 alkylenyl)-$C(O)R^h$, –(C_1-C_6 alkylenyl)-$C(O)OR^h$, -(C_1-C_6 alkylenyl)-$C(O)NR^jR^k$, –(C_1-C_6 alkylenyl)-NR^jR^k, –(C_1-C_6

alkylenyl)-N(R^h)C(O)R^i, -(C_1-C_6 alkylenyl)-N(R^h)S(O)$_2R^i$, –(C_1-C_6 alkylenyl)-N(R^h)C(O)O(R^i), –(C_1-C_6 alkylenyl)-N(R^h)C(O)NR^jR^k, or -(C_1-C_6 alkylenyl)-CN;

R^h, R^j, R^k, at each occurrence, are each independently hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl; and

R^i, at each occurrence, is independently C_1-C_6 alkyl or C_1-C_6 haloalkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen, -S(O)$_2R^{2a}$, or -N(R^{2b})S(O)$_2R^{2a}$;

R^{2a} is C_1-C_3 alkyl; and

R^{2b} is hydrogen.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^y is methyl,

R^1 is hydrogen, and

R^{x1}, G^1, R^3, and R^4, are selected from (i).

4. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein

R^3 is R^{1a};

R^4 is R^{1a}; and

G^1 is phenyl, C_3-C_6 cycloalkyl, or C_4-C_6 heterocycle, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^v groups.

5. The compound of claim 4 or a pharmaceutically acceptable salt thereof, wherein

R^{1a} is hydrogen; and

G^1 is phenyl or C_3-C_6 cycloalkyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^v groups.

6. The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein

R^2 is hydrogen, -S(O)$_2R^{2a}$, or -N(R^{2b})S(O)$_2R^{2a}$.

7. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

4-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-6-methyl-2-{[4-(pyridin-4-yl)piperazin-1-yl]methyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-6-methyl-2-{[4-(1,3-thiazol-2-yl)piperazin-1-yl]methyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-6-methyl-2-{[4-(pyrazin-2-yl)piperazin-1-yl]methyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-6-methyl-2-{[4-(pyrimidin-2-yl)piperazin-1-yl]methyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-6-methyl-2-{[4-(pyridin-3-yl)piperazin-1-yl]methyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; and

4-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-2-[3-(dimethylamino)prop-1-yn-1-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
R^y is methyl,
R^1 is hydrogen, and
R^{x1}, G^1, R^3, and R^4, are selected from (ii).

9. The compound of claim 8 or a pharmaceutically acceptable salt thereof, wherein
R^{x1} is hydrogen or $-C(O)NR^{bx1}R^{cx1}$;
R^3 is R^{1a};
R^4 is R^{1a}; and
G^1 is phenyl, C_3-C_6 cycloalkyl, or C_4-C_6 heterocycle, wherein each G^1 is substituted with one R^u group and is optionally further substituted with 1, 2, or 3 R^v groups.

10. The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein

R^{1a} is hydrogen; and

R^2 is hydrogen, $-S(O)_2R^{2a}$, or $-N(R^{2b})S(O)_2R^{2a}$.

11. The compound of claim 8 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

N-cyclopropyl-3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]benzamide;

6-methyl-4-[2-{3-[(4-methylpiperazin-1-yl)carbonyl]phenoxy}-5-(methylsulfonyl)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[3-({4-[2-(1H-imidazol-1-yl)ethyl]piperazin-1-yl}carbonyl)phenoxy]-5-(methylsulfonyl)phenyl}-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-(3-{[4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl}phenoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

N-cyclohexyl-3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]benzamide;

4-[2-(3-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenoxy)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]-N-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide;

4-[2-{3-[(4-cyclopentylpiperazin-1-yl)carbonyl]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[3-({4-[2-(dimethylamino)ethyl]piperazin-1-yl}carbonyl)phenoxy]-5-(methylsulfonyl)phenyl}-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(4-acetylpiperazin-1-yl)carbonyl]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-(3-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

N-(cyanomethyl)-N-methyl-3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]benzamide;

N-[2-(dimethylamino)ethyl]-3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]benzamide;

3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]-N-[(2R)-tetrahydrofuran-2-ylmethyl]benzamide;

3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]-N-[2-(pyrrolidin-1-yl)ethyl]benzamide;

N-(3,5-difluorobenzyl)-3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]benzamide;

N-(2,4-difluorobenzyl)-3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]benzamide;

N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}-1-phenylmethanesulfonamide;

4-methoxy-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

3-fluoro-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

4-fluoro-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

3-methoxy-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}-4-nitrobenzenesulfonamide;

4-acetyl-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

5-(dimethylamino)-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}naphthalene-1-sulfonamide;

N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}-4-(propan-2-yl)benzenesulfonamide;

2,4-difluoro-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

3-(difluoromethoxy)-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}cyclopropanesulfonamide;

3-methyl-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}-3-nitrobenzenesulfonamide;

4-fluoro-2-methyl-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

3,4-dimethoxy-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}-4-(methylsulfonyl)benzenesulfonamide;

2-cyano-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

4-cyano-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

3-cyano-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

2-chloro-4-fluoro-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}benzenesulfonamide;

1-methyl-N-{3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}-1H-imidazole-4-sulfonamide;

3-[({3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}amino)methyl]benzonitrile;

4-[({3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}amino)methyl]benzonitrile;

4-[2-{3-[(4-fluorobenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(2-methoxyethyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-{3-[(tetrahydrofuran-2-ylmethyl)amino]phenoxy}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(3-methoxybenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(2-fluorobenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(3-fluorobenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-(3-{[3-(trifluoromethoxy)benzyl]amino}phenoxy)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(2,4-dimethylbenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

2-[({3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}amino)methyl]benzonitrile;

4-[2-{3-[(2-chloro-4-fluorobenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(3,5-difluorobenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[3-({4-[3-(dimethylamino)propoxy]benzyl}amino)phenoxy]-5-(methylsulfonyl)phenyl}-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-(3-{[3-(dimethylamino)benzyl]amino}phenoxy)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-{3-[(tetrahydrofuran-3-ylmethyl)amino]phenoxy}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

N-{4-[({3-[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenoxy]phenyl}amino)methyl]phenyl}acetamide;

4-[2-{3-[(4-methoxybenzyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(cyclopropylmethyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{3-[(2-cyclopentylethyl)amino]phenoxy}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{4-chloro-2-[3-(morpholin-4-yl)prop-1-yn-1-yl]phenoxy}-5-(ethylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{4-chloro-2-[3-(morpholin-4-yl)propyl]phenoxy}-5-(ethylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-{[1-(phenylsulfonyl)piperidin-4-yl]amino}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-({1-[(dimethylamino)acetyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[2-({1-[3-(methylsulfanyl)propyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

N-{4-[(4-{[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenyl]amino}piperidin-1-yl)methyl]phenyl}acetamide;

6-methyl-4-[5-(methylsulfonyl)-2-{[1-(3,4,5-trimethoxybenzyl)piperidin-4-yl]amino}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-{[1-(thiophen-2-ylmethyl)piperidin-4-yl]amino}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-{2-[(1-{4-[3-(dimethylamino)propoxy]benzyl}piperidin-4-yl)amino]-5-(methylsulfonyl)phenyl}-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[2-({1-[(methylsulfanyl)acetyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-({1-[3-(2,3,4-trimethoxyphenyl)propanoyl]piperidin-4-yl}amino)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

1-[(4-{[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenyl]amino}piperidin-1-yl)carbonyl]cyclopropanecarboxamide;

4-[2-({1-[(4-methoxycyclohexyl)carbonyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{[1-(methoxyacetyl)piperidin-4-yl]amino}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[2-({1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]amino}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-({1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}amino)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[2-({1-[(4-methylphenyl)acetyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-{[1-(benzylsulfonyl)piperidin-4-yl]amino}-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-{5-(methylsulfonyl)-2-[(1-{[(E)-2-phenylethenyl]sulfonyl}piperidin-4-yl)amino]phenyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

N-{4-[(4-{[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenyl]amino}piperidin-1-yl)sulfonyl]phenyl}acetamide;

4-[2-({1-[(4-methoxyphenyl)sulfonyl]piperidin-4-yl}amino)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

3-[(4-{[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenyl]amino}piperidin-1-yl)sulfonyl]benzonitrile;

6-methyl-4-[5-(methylsulfonyl)-2-{[1-(thiophen-2-ylsulfonyl)piperidin-4-yl]amino}phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-({trans-4-[(thiophen-2-ylmethyl)amino]cyclohexyl}amino)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

N-(4-{[(trans-4-{[2-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(methylsulfonyl)phenyl]amino}cyclohexyl)amino]methyl}phenyl)acetamide;

4-[2-({trans-4-[(2,4-difluorobenzyl)amino]cyclohexyl}amino)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-[5-(methylsulfonyl)-2-({trans-4-[(naphthalen-2-ylmethyl)amino]cyclohexyl}amino)phenyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

4-[2-({trans-4-[(2-methoxyethyl)amino]cyclohexyl}amino)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

6-methyl-4-{2-[(trans-4-{[3-(methylsulfanyl)propyl]amino}cyclohexyl)amino]-5-(methylsulfonyl)phenyl}-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; and

4-[2-({trans-4-[(4-chlorobenzyl)amino]cyclohexyl}amino)-5-(methylsulfonyl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^y is methyl,

R^1 is hydrogen, and

R^{x1}, G^1, R^3, and R^4, are selected from (iii).

13. The compound of claim 12 or a pharmaceutically acceptable salt thereof, wherein

R^{x1} is hydrogen or $-C(O)NR^{bx1}R^{cx1}$;

R^4 is R^{1a}; and

G^1 is phenyl, C_3-C_6 cycloalkyl, or C_4-C_6 heterocycle, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^v groups.

14. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein

R^{1a} is hydrogen; and

G^1 is phenyl or C_3-C_6 cycloalkyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^v groups.

15. The compound of claim 14 or a pharmaceutically acceptable salt thereof, wherein

R^3 is -C(O)OH, -C(O)$NR^{3a}R^{3b}$, G^{3a}, -(C_1-C_6 alkylenyl)-OR^{3a}, -(C_1-C_6 alkylenyl)-$NR^{3a}R^{3b}$, -(C_1-C_6 alkylenyl)-G^{3a}, or -(C_1-C_6 alkylenyl)-G^{3a}-G^{3b}.

16. The compound of claim 15 or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen, -$S(O)_2R^{2a}$, or -$N(R^{2b})S(O)_2R^{2a}$.

17. The compound of claim 12 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

4-[2-(cyclopropylmethoxy)-4-(3-methyl-1H-pyrazol-5-yl)phenyl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

N-[4-(2,4-difluorophenoxy)-2-[(dimethylamino)methyl]-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-(piperidin-1-ylmethyl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-(morpholin-4-ylmethyl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-[(4-methylpiperazin-1-yl)methyl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-2-(hydroxymethyl)-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide;

N-{2-[(cyclopentylamino)methyl]-4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl}ethanesulfonamide;

5-(2,4-difluorophenoxy)-2-[(ethylsulfonyl)amino]-4-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide;

N-cyclopentyl-5-(2,4-difluorophenoxy)-2-[(ethylsulfonyl)amino]-4-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide;

5-(2,4-difluorophenoxy)-2-[(ethylsulfonyl)amino]-N,N-dimethyl-4-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide;

5-(2,4-difluorophenoxy)-2-[(ethylsulfonyl)amino]-4-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzoic acid;

5-(2,4-difluorophenoxy)-2-[(ethylsulfonyl)amino]-4-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide;

N-[4-(2,4-difluorophenoxy)-2-{[(2-hydroxyethyl)amino]methyl}-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide; and

N-{4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-[(2-phenylpyrrolidin-1-yl)methyl]phenyl}ethanesulfonamide

18. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^y is methyl,

R^1 is hydrogen, and

R^{x1}, G^1, R^3, and R^4, are selected from (iv).

19. The compound of claim 18 or a pharmaceutically acceptable salt thereof, wherein

R^{x1} is hydrogen;

R^3 is R^{1a}; and

G^1 is phenyl, C_3-C_6 cycloalkyl, or C_4-C_6 heterocycle, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^v groups.

20. The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein

R^{1a} is hydrogen; and

G^1 is phenyl or C_3-C_6 cycloalkyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 R^v groups.

21. The compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein

R^4 is optionally substituted C_3-C_6 cycloalkyl.

22. The compound of claim 21 or a pharmaceutically acceptable salt thereof, wherein

R^4 is optionally substituted cyclopropyl, and

R^2 is hydrogen, $-S(O)_2R^{2a}$, or $-N(R^{2b})S(O)_2R^{2a}$.

23. The compound of claim 18 or a pharmaceutically acceptable salt thereof, wherein the compound is

N-[3-cyclopropyl-4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide.

24. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

25. Use of a compound of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a subject.

26. The use of claim 25 wherein the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach

cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.